Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.55 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14265316 | 1.00 | CASP3 (0.55) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL119715 | 1.00 | CASP3 (0.55) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29400810 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL14265315 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL25268084 | 0.91 | CASP3 (0.50) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL25206792 | 0.91 | CASP3 (0.50) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL16060727 | 0.91 | CASP3 (0.50) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29400295 | 0.90 | CASP3 (0.48) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL1959804 | 0.90 | CASP3 (0.48) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29666630 | 0.90 | CASP3 (0.48) | CASP3MDM4TP53KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| US-12378206-B2 | Heteroaryl butanoic acid derivatives | NOVARTIS AG (CH) | 2025-08-05 | — | — | US | disclosed |
| US-20220411385-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2022-12-29 | — | — | US | disclosed |
| US-11453651-B2 | Heteroaryl butanoic acid derivatives | NOVARTIS AG (CH) | 2022-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411385-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | LTA4H, LTC4S, LTB4R | CASP3 1581/4885MDM4 2668/4885TP53 4240/4885 |
| US-12378206-B2 | Heteroaryl butanoic acid derivatives | LTA4H, LTC4S, LTB4R | CASP3 1454/4885MDM4 2574/4885TP53 4231/4885 |
| US-11453651-B2 | Heteroaryl butanoic acid derivatives | LTA4H, LTC4S, LTB4R | CASP3 1454/4885MDM4 2574/4885TP53 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.